公开(公告)号：US09790201B2

公开(公告)日：2017-10-17

申请号：US14910377

申请日：2014-08-07

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Sarah Bousba ,  Anne Goldby ,  Kerry Jenkins ,  Natasha Kinsella ,  Martin Teall

IPC: A61K31/4439 ,  A61K31/444 ,  A61K31/55 ,  C07D401/06 ,  C07D403/06 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/501 ,  C07D401/14

CPC classification number: C07D401/06 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/501 ,  A61K31/55 ,  C07D401/14 ,  C07D403/06

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R1, R2, R3 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

公开(公告)号：US09750748B2

公开(公告)日：2017-09-05

申请号：US14652484

申请日：2013-12-17

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： William Farnaby ,  Charlotte Fieldhouse ,  Katherine Hazel ,  Catrina Kerr ,  Natasha Kinsella ,  David Livermore ,  Kevin Merchant ,  David Miller

IPC: A61K31/55 ,  C07D405/04 ,  A61K31/501 ,  C07D403/04 ,  C07D237/20 ,  C07D401/04 ,  A61K45/06 ,  A61K31/50 ,  C07D237/16 ,  C07D237/22 ,  A61K31/277 ,  A61K31/496 ,  A61K31/519 ,  A61K31/53 ,  A61K31/551 ,  A61K31/554 ,  A61K33/00

CPC classification number: A61K31/55 ,  A61K31/277 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/519 ,  A61K31/53 ,  A61K31/551 ,  A61K31/554 ,  A61K33/00 ,  A61K45/06 ,  C07D237/16 ,  C07D237/20 ,  C07D237/22 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  A61K2300/00

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

公开(公告)号：US10287286B2

公开(公告)日：2019-05-14

申请号：US15558824

申请日：2016-03-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Saleh Ahmed ,  Gregory Barker ,  Hannah Canning ,  Richard Davenport ,  David Harrison ,  Kerry Jenkins ,  David Livermore ,  Susanne Wright ,  Natasha Kinsella

IPC: C07D471/04 ,  C07D487/04 ,  C07D519/00

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, Y1, Y2, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

公开(公告)号：US10160745B2

公开(公告)日：2018-12-25

申请号：US15702100

申请日：2017-09-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Sarah Bousba ,  Anne Goldby ,  Kerry Jenkins ,  Natasha Kinsella ,  Martin Teall

IPC: A61K31/454 ,  A61K31/4545 ,  C07D401/06 ,  C07D403/06 ,  A61K31/501 ,  A61K31/55 ,  C07D401/14

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R1, R2, R3 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions N containing them and their use in therapy.

公开(公告)号：US20180072714A1

公开(公告)日：2018-03-15

申请号：US15558824

申请日：2016-03-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Saleh Ahmed ,  Gregory Barker ,  Hannah Canning ,  Richard Davenport ,  David Harrison ,  Kerry Jenkins ,  David Livermore ,  Susanne Wright ,  Natasha Kinsella

IPC: C07D471/04 ,  C07D487/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D487/04 ,  C07D519/00

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, Y1, Y2, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

公开(公告)号：US20180009780A1

公开(公告)日：2018-01-11

申请号：US15702100

申请日：2017-09-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Sarah Bousba ,  Anne Goldby ,  Kerry Jenkins ,  Natasha Kinsella ,  Martin Teall

IPC: C07D401/06 ,  C07D401/14 ,  A61K31/55 ,  A61K31/501 ,  A61K31/4545 ,  C07D403/06 ,  A61K31/454

CPC classification number: C07D401/06 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/501 ,  A61K31/55 ,  C07D401/14 ,  C07D403/06

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R1, R2, R3 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions N containing them and their use in therapy.